AbbVie takes aim at Gilead and BMS with 8-week hep C treatment

Of Interest

AbbVie takes aim at Gilead and BMS with 8-week hep C treatment
Richard Staines
AbbVie is aiming to steal sales from hep C drugs from Gilead and BMS with a new combination offering a shorter, eight-week treatment for the most difficult-to-treat form of the disease.

Results presented at the International Liver Congress (ILC) in Amsterdam showed 95% of genotype 3 patients on its pan-genotypic regimen of glecaprevir+pibrentasvir were free of disease, 12 weeks after completing an eight-week treatment course.

The results were based on a previously untreated, cirrhosis-free, 157-patient arm of the ENDURANCE-3 study.

Another arm of the trial also met its goal, matching the performance of BMS’ Daclinza(daclatasvir) plus Gilead’s Sovaldi (sofosbuvir) over 12 weeks in genotype 3.

The Daclinza and Sovaldi combination is current standard of care for genotype 3 hepatitis, but AbbVie is attempting to produce a more patient-friendly alternative with a shorter regimen.
Continue reading...

Meeting Updates
Updates On This Blog
Hep C 5-minute videos - Summary Of The International Liver Congress™ (ILC) 2017